BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, Ingram JR, Kanni T, Karagiannidis I, Martorell A, Matusiak Ł, Pinter A, Prens EP, Presser D, Schneider-Burrus S, von Stebut E, Szepietowski JC, van der Zee HH, Wilden SM, Sabat R; European Hidradenitis Suppurativa Foundation Investigator Group. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017;177:1401-9. [PMID: 28636793 DOI: 10.1111/bjd.15748] [Cited by in Crossref: 117] [Cited by in F6Publishing: 89] [Article Influence: 29.3] [Reference Citation Analysis]
Number Citing Articles
1 Wollina U, Brzezinski P, Koch A, Philipp-Dormston WG. Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa-A narrative review. Dermatol Ther 2020;33:e13877. [PMID: 32558202 DOI: 10.1111/dth.13877] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, Weisman J, Gu Y, Williams DA, Jemec GBE. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 2019;80:60-69.e2. [PMID: 29860040 DOI: 10.1016/j.jaad.2018.05.040] [Cited by in Crossref: 68] [Cited by in F6Publishing: 52] [Article Influence: 22.7] [Reference Citation Analysis]
3 Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers 2020;6:18. [PMID: 32165620 DOI: 10.1038/s41572-020-0149-1] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 56.0] [Reference Citation Analysis]
4 Sabat R. [Acne inversa/hidradenitis suppurativa: A challenge for the future]. Hautarzt 2017;68:994-8. [PMID: 29110042 DOI: 10.1007/s00105-017-4079-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Rondags A, van Straalen KR, van Hasselt JR, Janse IC, Ardon CB, Vossen ARJV, Prens EP, van der Zee HH, Horváth B. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment. Br J Dermatol 2019;180:1214-20. [PMID: 30512186 DOI: 10.1111/bjd.17508] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
6 Bettoli V, Manfredini M, Calamo G, Forconi R, Bencivelli D, Mantovani L, Pellacani G, Corazza M. Long-term adalimumab treatment of hidradenitis suppurativa: Results and practical insights from a real-life experience. Dermatol Ther 2018;31:e12737. [PMID: 30295378 DOI: 10.1111/dth.12737] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
7 Vaiopoulos AG, Nikolakis G, Zouboulis CC. Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. J Eur Acad Dermatol Venereol 2020;34:2140-6. [PMID: 32324936 DOI: 10.1111/jdv.16520] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
8 Burzi L, Repetto F, Ramondetta A, Rozzo G, Licciardello M, Ribero S, Quaglino P, Dapavo P. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatol Ther 2021;34:e14930. [PMID: 33665949 DOI: 10.1111/dth.14930] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R, Krueger JG. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data. J Am Acad Dermatol 2020;82:1150-7. [PMID: 31881294 DOI: 10.1016/j.jaad.2019.12.044] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
10 Nikolakis G, Kyrgidis A, Zouboulis CC. Is There a Role for Antiandrogen Therapy for Hidradenitis Suppurativa? A Systematic Review of Published Data. Am J Clin Dermatol 2019;20:503-13. [DOI: 10.1007/s40257-019-00442-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
11 Navrazhina K, Garcet S, Zheng X, Hur HB, Frew JW, Krueger JG. High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. J Allergy Clin Immunol 2021:S0091-6749(21)00832-0. [PMID: 34081946 DOI: 10.1016/j.jaci.2021.05.027] [Reference Citation Analysis]
12 Scala E, Di Caprio R, Cacciapuoti S, Caiazzo G, Fusco A, Tortorella E, Fabbrocini G, Balato A. A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26. Br J Dermatol 2019;181:1038-45. [PMID: 30829398 DOI: 10.1111/bjd.17854] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
13 Sayed CJ, Hsiao JL, Okun MM; Hidradenitis Suppurativa Foundation Women's Health Subcommittee. Clinical Epidemiology and Management of Hidradenitis Suppurativa. Obstet Gynecol 2021;137:731-46. [PMID: 33706337 DOI: 10.1097/AOG.0000000000004321] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gulliver W, Alavi A, Wiseman MC, Gooderham MJ, Rao J, Alam MS, Papp KA, Desjardins O, Jean C. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. J Eur Acad Dermatol Venereol 2021. [PMID: 34378812 DOI: 10.1111/jdv.17598] [Reference Citation Analysis]
15 Bragazzi NL, Riccò M, Pacifico A, Malagoli P, Kridin K, Pigatto P, Damiani G. COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration. Dermatol Ther 2020;33:e13508. [PMID: 32415727 DOI: 10.1111/dth.13508] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 13.0] [Reference Citation Analysis]
16 Witte-Händel E, Wolk K, Tsaousi A, Irmer ML, Mößner R, Shomroni O, Lingner T, Witte K, Kunkel D, Salinas G, Jodl S, Schmidt N, Sterry W, Volk HD, Giamarellos-Bourboulis EJ, Pokrywka A, Döcke WD, Schneider-Burrus S, Sabat R. The IL-1 Pathway Is Hyperactive in Hidradenitis Suppurativa and Contributes to Skin Infiltration and Destruction. J Invest Dermatol 2019;139:1294-305. [PMID: 30528824 DOI: 10.1016/j.jid.2018.11.018] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 18.0] [Reference Citation Analysis]
17 Arenbergerova M, Gkalpakiotis S, Marques E, Arenberger P, Dahmen R, Smetanova A. Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab. J Eur Acad Dermatol Venereol 2021;35. [DOI: 10.1111/jdv.17151] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Salvador-Rodríguez L, Arias-Santiago S, Molina-Leyva A. Ultrasound-assisted intralesional corticosteroid infiltrations for patients with hidradenitis suppurativa. Sci Rep 2020;10:13363. [PMID: 32770058 DOI: 10.1038/s41598-020-70176-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Martorell A, Giovanardi G, Gomez-palencia P, Sanz-motilva V. Defining Fistular Patterns in Hidradenitis Suppurativa: Impact on the Management. Dermatol Surg 2019;45:1237-44. [DOI: 10.1097/dss.0000000000001916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
20 Sabat R, Tsaousi A, Rossbacher J, Kurzen H, Fadai T, Schwichtenberg U, Schneider-Burrus S, Kokolakis G, Wolk K. [Acne inversa/hidradenitis suppurativa: An update]. Hautarzt 2017;68:999-1006. [PMID: 29159469 DOI: 10.1007/s00105-017-4082-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
21 Grand D, Navrazhina K, Frew JW. A Scoping Review of Non-invasive Imaging Modalities in Dermatological Disease: Potential Novel Biomarkers in Hidradenitis Suppurativa. Front Med (Lausanne) 2019;6:253. [PMID: 31781567 DOI: 10.3389/fmed.2019.00253] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
22 Krajewski PK, Matusiak Ł, von Stebut E, Schultheis M, Kirschner U, Nikolakis G, Szepietowski JC. Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. Life (Basel) 2021;11:34. [PMID: 33429896 DOI: 10.3390/life11010034] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
23 Hessam S, Scholl L, Sand M, Schmitz L, Reitenbach S, Bechara FG. A Novel Severity Assessment Scoring System for Hidradenitis Suppurativa. JAMA Dermatol 2018;154:330-5. [PMID: 29417136 DOI: 10.1001/jamadermatol.2017.5890] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 13.0] [Reference Citation Analysis]
24 Cuenca‐barrales C, Salvador‐rodríguez L, Arias‐santiago S, Molina‐leyva A. Pre‐operative ultrasound planning in the surgical management of patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020;34:2362-7. [DOI: 10.1111/jdv.16435] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Rosales Santillan M, Morss PC, Porter ML, Kimball AB. Biologic therapies for the treatment of hidradenitis suppurativa. Expert Opin Biol Ther 2020;20:621-33. [PMID: 32077334 DOI: 10.1080/14712598.2020.1732918] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Marzano AV, Moltrasio C, Genovese G, Muratori S, Dapavo P, Fabbrocini G, Patrizi A, Sechi A, Micali G, Pellegrino M, Gisondi P, Dini V, Bianchi L, Fania L, Offidani A, Prignano F, Atzori L, Miraglia E, Cannavò SP, Bettoli V, Stingeni L, Balestri R, Venturini M, Peris K. Hidradenitis suppurativa and adalimumab in the COVID-19 era. Eur J Dermatol 2020;30:748-9. [PMID: 33337329 DOI: 10.1684/ejd.2020.3927] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 Calao M, Wilson JL, Spelman L, Billot L, Rubel D, Watts AD, Jemec GBE. Hidradenitis Suppurativa (HS) prevalence, demographics and management pathways in Australia: A population-based cross-sectional study. PLoS One 2018;13:e0200683. [PMID: 30040827 DOI: 10.1371/journal.pone.0200683] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 9.3] [Reference Citation Analysis]
28 von Laffert M, Hunger RE, Navarini AA, Zouboulis CC. [Clinical, pathology-associated and molecular biomarkers of hidradenitis suppurativa/acne inversa]. Hautarzt 2021;72:666-75. [PMID: 34213572 DOI: 10.1007/s00105-021-04848-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Montero-Vilchez T, Salvador-Rodriguez L, Sanchez-Diaz M, Cuenca-Barrales C, Martinez-Lopez A, Arias-Santiago S, Molina-Leyva A. Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice. Dermatol Ther 2020;33:e14254. [PMID: 32860480 DOI: 10.1111/dth.14254] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Kovacs M, Podda M. Guselkumab in the treatment of severe hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019;33:e140-1. [PMID: 30480844 DOI: 10.1111/jdv.15368] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
31 Włodarek K, Ponikowska M, Matusiak Ł, Szepietowski JC. Biologics for hidradenitis suppurativa: an update. Immunotherapy 2019;11:45-59. [PMID: 30702012 DOI: 10.2217/imt-2018-0090] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
32 Krajewski PK, Szukała W, Lichawska-Cieślar A, Matusiak Ł, Jura J, Szepietowski JC. MCPIP1/Regnase-1 Expression in Keratinocytes of Patients with Hidradenitis Suppurativa: Preliminary Results. Int J Mol Sci 2021;22:7241. [PMID: 34298861 DOI: 10.3390/ijms22147241] [Reference Citation Analysis]
33 Kirby JS, Butt M, King T. Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa. Br J Dermatol 2020;182:940-8. [PMID: 31233623 DOI: 10.1111/bjd.18244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
34 Prens EP, Lugo-Somolinos AM, Paller AS, Kerdel F, Duan Y, Teixeira HD, Longcore M, Kimball AB. Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. Am J Clin Dermatol 2020;21:579-90. [PMID: 32077014 DOI: 10.1007/s40257-020-00504-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
35 van Straalen KR, Tzellos T, Guillem P, Benhadou F, Cuenca-Barrales C, Daxhelet M, Daoud M, Efthymiou O, Giamarellos-Bourboulis EJ, Jemec GBE, Katoulis AC, Koenig A, Lazaridou E, Marzano AV, Matusiak Ł, Molina-Leyva A, Moltrasio C, Pinter A, Potenza C, Romaní J, Saunte DM, Skroza N, Stergianou D, Szepietowski J, Trigoni A, Vilarrasa E, van der Zee HH. The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. J Am Acad Dermatol 2021;85:369-78. [PMID: 33484766 DOI: 10.1016/j.jaad.2020.12.089] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Wohlmuth-Wieser I, Alhusayen R. Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. Int J Dermatol 2021;60:e140-1. [PMID: 33247833 DOI: 10.1111/ijd.15286] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
37 Flood KS, Porter ML, Kimball AB. Biologic Treatment for Hidradenitis Suppurativa. Am J Clin Dermatol 2019;20:625-38. [DOI: 10.1007/s40257-019-00439-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
38 Kokolakis G, Sabat R. Distinguishing Mild, Moderate, and Severe Hidradenitis Suppurativa. JAMA Dermatol 2018;154:971-2. [PMID: 29926079 DOI: 10.1001/jamadermatol.2018.1599] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Thorlacius L, Garg A, Riis P, Nielsen S, Bettoli V, Ingram J, Marmol V, Matusiak L, Pascual J, Revuz J, Sartorius K, Tzellos T, Zee H, Zouboulis C, Saunte D, Gottlieb A, Christensen R, Jemec G. Inter‐rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa. Br J Dermatol 2019;181:483-91. [DOI: 10.1111/bjd.17716] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
40 Aarts P, Dudink K, Vossen ARJV, van Straalen KR, Ardon CB, Prens EP, van der Zee HH. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. Drugs 2021;81:1397-410. [PMID: 34283386 DOI: 10.1007/s40265-021-01566-2] [Reference Citation Analysis]
41 Kanni T, Argyropoulou M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period. Clin Exp Dermatol 2021;46:162-3. [PMID: 32516832 DOI: 10.1111/ced.14333] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
42 Grand D, Frew JW, Navrazhina K, Krueger JG. Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity. Br J Dermatol 2021;184:688-96. [PMID: 32602132 DOI: 10.1111/bjd.19343] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
43 Lim SYD, Oon HH. Systematic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics 2019;13:53-78. [PMID: 31190730 DOI: 10.2147/BTT.S199862] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
44 Frew JW, Navrazhina K, Grand D, Sullivan-Whalen M, Gilleaudeau P, Garcet S, Ungar J, Krueger JG. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study. J Am Acad Dermatol 2020;83:1341-8. [PMID: 32416208 DOI: 10.1016/j.jaad.2020.05.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 21.0] [Reference Citation Analysis]
45 Prignano F, Pescitelli L, Giani I, Dini V, Romanelli M; and the Tuscany HS Working Group. Tuscan consensus on the diagnosis and treatment of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2019;33 Suppl 6:21-4. [PMID: 31535762 DOI: 10.1111/jdv.15825] [Reference Citation Analysis]
46 Agut-busquet E, Romaní J, Ribera M, Luelmo J. Hidradenitis suppurativa of the nape: Description of an atypical phenotype related to severe early-onset disease in men. J Dermatol 2019;46:149-53. [DOI: 10.1111/1346-8138.14722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
47 Shavit E, Alavi A, Bechara FG, Bennett RG, Bourcier M, Cibotti R, Daveluy S, Frew JW, Garg A, Hamzavi I, Hoffman LK, Hsaio J, Kirby JS, Lev-Tov H, Martinez E, Micheletti R, Naik HB, Nassif A, Nicholson C, Parks-Miller A, Patel Z, Piguet V, Ramesh M, Resnik B, Sayed C, Schultz G, Siddiqui A, Tan J, Wortsman X, Lowes MA. Proceeding report of the Second Symposium on Hidradenitis Suppurativa Advances (SHSA) 2017. Exp Dermatol 2019;28:94-103. [PMID: 30484907 DOI: 10.1111/exd.13849] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
48 Kanni T, Zenker O, Habel M, Riedemann N, Giamarellos-Bourboulis EJ. Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis? Br J Dermatol 2018;179:413-9. [PMID: 29405257 DOI: 10.1111/bjd.16428] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
49 Li X, Jiang L, Huang Y, Ren Z, Liang X, Wang P. A gene dysfunction module reveals the underlying pathogenesis of hidradenitis suppurativa: An update. Australas J Dermatol 2019;61. [DOI: 10.1111/ajd.13107] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Brandao L, Moura R, Tricarico PM, Gratton R, Genovese G, Moltrasio C, Garcovich S, Boniotto M, Crovella S, Marzano AV. Altered keratinization and vitamin D metabolism may be key pathogenetic pathways in syndromic hidradenitis suppurativa: a novel whole exome sequencing approach. J Dermatol Sci 2020;99:17-22. [PMID: 32518053 DOI: 10.1016/j.jdermsci.2020.05.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
51 Damiani G, Leone S, Fajgenbaum K, Bragazzi NL, Pacifico A, Conic RR, Pigatto PD, Maiorana C, Poli P, Berti E, Pace MC, Malagoli P, Bettoli V, Fiore M. Nonalcoholic fatty liver disease prevalence in an Italian cohort of patients with hidradenitis suppurativa: A multi-center retrospective analysis. World J Hepatol 2019;11:391-401. [PMID: 31114643 DOI: 10.4254/wjh.v11.i4.391] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
52 Naik HB. Importance of Standardized Nomenclature to Advance Hidradenitis Suppurativa Research and Clinical Care. JAMA Dermatol 2021;157:381-3. [PMID: 33688911 DOI: 10.1001/jamadermatol.2020.5466] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Ramos-Alejos-Pita C, Arias-Santiago S, Molina-Leyva A. Quality of Life in Cohabitants of Patients with Hidradenitis Suppurativa: A Cross-sectional Study. Int J Environ Res Public Health 2020;17:E6000. [PMID: 32824800 DOI: 10.3390/ijerph17166000] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
54 Tzellos T, Zouboulis CC. Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice. Dermatol Ther (Heidelb) 2020;10:63-71. [PMID: 31955366 DOI: 10.1007/s13555-020-00354-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
55 Gergely LH, Gáspár K, Brodszky V, Kinyó Á, Szegedi A, Remenyik É, Kiss NF, Bató A, Péntek M, Gulácsi L, Sárdy M, Bánvölgyi A, Wikonkál N, Rencz F. Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020;34:2584-92. [PMID: 32618022 DOI: 10.1111/jdv.16642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
56 Chernyshov PV, Zouboulis CC, Tomas-Aragones L, Jemec GB, Svensson A, Manolache L, Tzellos T, Sampogna F, Pustisek N, van der Zee HH, Marron SE, Spillekom-van Koulil S, Bewley A, Linder D, Abeni D, Szepietowski JC, Augustin M, Finlay AY. Quality of life measurement in hidradenitis suppurativa: position statement of the European Academy of Dermatology and Venereology task forces on Quality of Life and Patient-Oriented Outcomes and Acne, Rosacea and Hidradenitis Suppurativa. J Eur Acad Dermatol Venereol 2019;33:1633-43. [PMID: 31037773 DOI: 10.1111/jdv.15519] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
57 Rosi E, Pescitelli L, Ricceri F, Di Cesare A, Novelli A, Pimpinelli N, Prignano F. Clindamycin as unique antibiotic choice in Hidradenitis Suppurativa. Dermatologic Therapy 2019;32:e12792. [DOI: 10.1111/dth.12792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
58 Zouboulis CC, Frew JW, Giamarellos-Bourboulis EJ, Jemec GBE, Del Marmol V, Marzano AV, Nikolakis G, Sayed CJ, Tzellos T, Wolk K, Prens EP. Target molecules for future hidradenitis suppurativa treatment. Exp Dermatol 2021;30 Suppl 1:8-17. [PMID: 34085329 DOI: 10.1111/exd.14338] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
59 Frew JW, Jiang CS, Singh N, Grand D, Navrazhina K, Vaughan R, Krueger JG. Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. Clin Exp Dermatol 2021;46:306-13. [PMID: 32931599 DOI: 10.1111/ced.14448] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
60 Zouboulis CC, Bechara FG, Dickinson-Blok JL, Gulliver W, Horváth B, Hughes R, Kimball AB, Kirby B, Martorell A, Podda M, Prens EP, Ring HC, Tzellos T, van der Zee HH, van Straalen KR, Vossen ARJV, Jemec GBE. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization - systematic review and recommendations from the HS ALLIANCE working group. J Eur Acad Dermatol Venereol 2019;33:19-31. [PMID: 30176066 DOI: 10.1111/jdv.15233] [Cited by in Crossref: 67] [Cited by in F6Publishing: 46] [Article Influence: 22.3] [Reference Citation Analysis]
61 Marzano AV, Genovese G, Casazza G, Moltrasio C, Dapavo P, Micali G, Sirna R, Gisondi P, Patrizi A, Dini V, Bianchini D, Bianchi L, Fania L, Prignano F, Offidani A, Atzori L, Bettoli V, Cannavò SP, Venturini M, Bongiorno MR, Costanzo A, Fabbrocini G, Peris K. Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. Br J Dermatol 2021;184:133-40. [PMID: 32119111 DOI: 10.1111/bjd.18983] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 21.0] [Reference Citation Analysis]
62 Magalhães RF, Rivitti-Machado MC, Duarte GV, Souto R, Nunes DH, Chaves M, Hirata SH, Ramos AMC. Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology. An Bras Dermatol 2019;94:7-19. [PMID: 31166401 DOI: 10.1590/abd1806-4841.20198607] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
63 Ingram JR. Refining the hidradenitis suppurativa Hurley staging system for mild, moderate and severe disease. Br J Dermatol 2019;180:991-2. [DOI: 10.1111/bjd.17769] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
64 Sanchez-Diaz M, Martinez-Lopez A, Salvador-Rodriguez L, Montero-Vilchez T, Arias-Santiago S, Molina-Leyva A. The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema. Dermatol Ther 2021;34:e14829. [PMID: 33527618 DOI: 10.1111/dth.14829] [Reference Citation Analysis]
65 Ovadja ZN, Schuit MM, van der Horst CMAM, Lapid O. Inter- and intrarater reliability of Hurley staging for hidradenitis suppurativa. Br J Dermatol 2019;181:344-9. [PMID: 30585304 DOI: 10.1111/bjd.17588] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
66 Del Duca E, Morelli P, Bennardo L, Di Raimondo C, Nisticò SP. Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. Int J Mol Sci 2020;21:E8436. [PMID: 33182701 DOI: 10.3390/ijms21228436] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
67 Schneider-Burrus S, Tsaousi A, Barbus S, Huss-Marp J, Witte K, Wolk K, Fritz B, Sabat R. Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients. Front Med (Lausanne) 2021;8:676241. [PMID: 33987196 DOI: 10.3389/fmed.2021.676241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
68 Pavon Blanco A, Turner M, Petrof G, Weinman J. To what extent do disease severity and illness perceptions explain depression, anxiety and quality of life in hidradenitis suppurativa? Br J Dermatol 2018;180:338-45. [DOI: 10.1111/bjd.17123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
69 Holcomb ZE, Porter ML, Kimball AB. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. Expert Opin Drug Saf 2021;:1-15. [PMID: 33910441 DOI: 10.1080/14740338.2021.1924147] [Reference Citation Analysis]
70 Micali G, Lacarrubba F. Standardized classification tools in dermatology: time to focus on cutaneous warts. Br J Dermatol 2018;178:330. [PMID: 29441545 DOI: 10.1111/bjd.16165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
71 van Straalen KR, Schneider-Burrus S, Prens EP. Current and future treatment of hidradenitis suppurativa. Br J Dermatol 2020;183:e178-87. [PMID: 29981245 DOI: 10.1111/bjd.16768] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
72 Zouboulis CC, Goyal M. Hidradenitis Suppurativa. In: Orfanos CE, Zouboulis CC, Assaf C, editors. Pigmented Ethnic Skin and Imported Dermatoses. Cham: Springer International Publishing; 2018. pp. 219-28. [DOI: 10.1007/978-3-319-69422-1_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Bettoli V, Manfredini M, Massoli L, Carillo C, Barozzi A, Amendolagine G, Ruina G, Musmeci D, Libanore M, Curtolo A, Mantovani L, Contini C, Pellacani G, Corazza M. Rates of antibiotic resistance/sensitivity in bacterial cultures of hidradenitis suppurativa patients. J Eur Acad Dermatol Venereol 2019;33:930-6. [PMID: 30394587 DOI: 10.1111/jdv.15332] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
74 Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos‐bourboulis EJ, Fabbrocini G, Frew JW, Fujita H, González‐lópez MA, Guillem P, Gulliver WPF, Hamzavi I, Hayran Y, Hórvath B, Hüe S, Hunger RE, Ingram JR, Jemec GB, Ju Q, Kimball AB, Kirby JS, Konstantinou MP, Lowes MA, Macleod AS, Martorell A, Marzano AV, Matusiak Ł, Nassif A, Nikiphorou E, Nikolakis G, Nogueira da Costa A, Okun MM, Orenstein LA, Pascual JC, Paus R, Perin B, Prens EP, Röhn TA, Szegedi A, Szepietowski JC, Tzellos T, Wang B, van der Zee HH. What causes hidradenitis suppurativa ?—15 years after. Exp Dermatol 2020;29:1154-70. [DOI: 10.1111/exd.14214] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 17.0] [Reference Citation Analysis]
75 Chernyshov PV, Finlay AY, Tomas-Aragones L, Poot F, Sampogna F, Marron SE, Zemskov SV, Abeni D, Tzellos T, Szepietowski JC, Zouboulis CC. Quality of Life in Hidradenitis Suppurativa: An Update. Int J Environ Res Public Health 2021;18:6131. [PMID: 34204126 DOI: 10.3390/ijerph18116131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
76 Giamarellos-Bourboulis EJ, Argyropoulou M, Kanni T, Spyridopoulos T, Otto I, Zenker O, Guo R, Riedemann NC. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. Br J Dermatol 2020;183:176-8. [PMID: 31954061 DOI: 10.1111/bjd.18877] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 22.0] [Reference Citation Analysis]
77 Goldfarb N, Ingram JR, Jemec GBE, Naik HB, Piguet V, Hyde MJ, Freese R, Lowes MA, Alavi A. Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa. Br J Dermatol 2020;182:240-2. [PMID: 31286486 DOI: 10.1111/bjd.18335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
78 Nazzaro G, Calzari P, Passoni E, Vaienti S, Moltrasio C, Barbareschi M, Muratori S, Veraldi S, Marzano AV. Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients. Dermatol Ther 2021;34:e14706. [PMID: 33368976 DOI: 10.1111/dth.14706] [Reference Citation Analysis]
79 Eşer E, Engin B, Yüksel P, Kocazeybek BS, Kutlubay Z, Serdaroğlu S, Aşkın Ö. Relationship between fecal calprotectin level and disease activity in patients with hidradenitis suppurativa. Dermatologic Therapy 2020;33. [DOI: 10.1111/dth.13232] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
80 Damiani G, Mahroum N, Pigatto PDM, Pacifico A, Malagoli P, Tiodorovic D, Conic RR, Amital H, Bragazzi NL, Watad A, Adawi M. The Safety and Impact of a Model of Intermittent, Time-Restricted Circadian Fasting ("Ramadan Fasting") on Hidradenitis Suppurativa: Insights from a Multicenter, Observational, Cross-Over, Pilot, Exploratory Study. Nutrients 2019;11:E1781. [PMID: 31374976 DOI: 10.3390/nu11081781] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
81 Oranges T, Vitali S, Benincasa B, Izzetti R, Lencioni R, Caramella D, Romanelli M, Dini V. Advanced evaluation of hidradenitis suppurativa with ultra‐high frequency ultrasound: A promising tool for the diagnosis and monitoring of disease progression. Skin Res Technol 2020;26:513-9. [DOI: 10.1111/srt.12823] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
82 Zouboulis CC, Chernyshov PV. Hidradenitis suppurativa-specific, patient-reported outcome measures. J Eur Acad Dermatol Venereol 2021;35:1420-1. [PMID: 34139050 DOI: 10.1111/jdv.17306] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Frew J, Navrazhina K, Sullivan‐whalen M, Gilleaudeau P, Garcet S, Krueger J. Weekly administration of brodalumab in hidradenitis suppurativa: an open‐label cohort study. Br J Dermatol 2021;184:350-2. [DOI: 10.1111/bjd.19478] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
84 Akoglu G, Yildiz I, Karaismailoğlu E, Esme P. Disease severity and poor mental health are the main predictors of stigmatization in patients with hidradenitis suppurativa. Dermatol Ther 2021;34:e14910. [PMID: 33619860 DOI: 10.1111/dth.14910] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Takeda K, Kikuchi K, Kanazawa Y, Yamasaki K, Aiba S. Ustekinumab treatment for hidradenitis suppurativa. J Dermatol 2019;46:1215-8. [DOI: 10.1111/1346-8138.15122] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
86 Jørgensen AR, Yao Y, Thomsen SF. Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa. Case Rep Dermatol Med 2018;2018:8685136. [PMID: 29850284 DOI: 10.1155/2018/8685136] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
87 Montero-Vilchez T, Valenzuela-Amigo A, Cuenca-Barrales C, Arias-Santiago S, Leyva-García A, Molina-Leyva A. The Role of Oral Contraceptive Pills in Hidradenitis Suppurativa: A Cohort Study. Life (Basel) 2021;11:697. [PMID: 34357069 DOI: 10.3390/life11070697] [Reference Citation Analysis]
88 Frew JW. Assessing the efficacy of new biologic therapies in hidradenitis suppurativa: consistency vs. bias in outcome measures in moderate and severe disease. J Eur Acad Dermatol Venereol 2019;33:e298-300. [PMID: 30875132 DOI: 10.1111/jdv.15572] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
89 Nguyen T, Damiani G, Orenstein L, Hamzavi I, Jemec G. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol 2021;35:50-61. [DOI: 10.1111/jdv.16677] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 23.0] [Reference Citation Analysis]